Search the Newsreel

(HTGC) Price Dynamics and Execution-Aware Positioning

This article provides an AI-driven analysis of Hercules Capital Inc. (NASDAQ: HTGC), highlighting a strong near and mid-term sentiment but a weak long-term outlook. It identifies compelling upside potential due to the absence of resistance levels above the current price. The analysis includes three …

Earnings call transcript: Insight Molecular Diagnostics posts mixed Q2 2026 results

* Insight Molecular Diagnostics Inc. (IMDX [https://seekingalpha.com/symbol/IMDX]) is scheduled to announce Q2 earnings results on Monday, August 10th, after market close. * The consensus EPS estimate is -$0.25, [https://seekingalpha.com/symbol/IMDX/earnings/estimates] and the consensus revenue estimate is $0.44M * Over the last year, IMDX has beaten …

Insight Molecular Diagnostics earnings beat, revenue fell short of estimates

Insight Molecular Diagnostics (NASDAQ: IMDX) reported second-quarter EPS of $-0.230, exceeding analyst estimates of $-0.240. However, the company's revenue of $240K fell short of the consensus estimate of $470.85K. Despite the revenue miss, the company's stock price has shown significant volatility, being down -25.700% …

Insight Molecular Diagnostics: Q2 Earnings Snapshot

The provided content is not an article but rather a privacy notice or a placeholder. It does not contain any information about Insight Molecular Diagnostics or its Q2 earnings. Therefore, no meaningful summary can be generated.

Form 8K Insight Molecular Diagnostics Inc For: 10 August By Investing.com

This article announces the filing of a Form 8K by Insight Molecular Diagnostics Inc. on August 10. The filing is a standard regulatory announcement, and the article provides no further details beyond the company name and filing date. It appears to be a placeholder …

Insight Molecular Diagnostics (Nasdaq: IMDX) reports steep revenue drop but bolsters cash

Insight Molecular Diagnostics (IMDX) reported a steep revenue drop in Q2 2026, with net revenue down sharply to $239,000 from $518,000 in the prior year, and a net loss of $11.3 million. Despite the revenue decline and increased operating expenses, the company bolstered its …

IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx

Insight Molecular Diagnostics Inc. (IMDX) reported its Q2 2026 results and provided an update on the FDA review of its GraftAssureDx product. The company is progressing with the FDA, expecting marketing authorization soon, and highlighted favorable Medicare reimbursement policy changes. IMDX also shared clinical …

Ocular Therapeutix, Inc. $OCUL Shares Acquired by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company significantly increased its stake in Ocular Therapeutix (NASDAQ:OCUL) by 145.9% in the first quarter, now owning 227,808 shares. This acquisition is part of a broader trend of institutional investment, with hedge funds and institutional investors collectively owning 59.21% of …

AirSculpt anticipates $12M-$14M adjusted EBITDA while rolling out AlloClae partnership

Earnings Call Insights: AirSculpt Technologies, Inc. (AIRS) Q2 2026 MANAGEMENT VIEW * “For the quarter, on a comparable basis, we delivered stable revenue and positive same-center case growth,” said (CEO & Director Yogesh Jashnani), adding that “Center sales began the quarter positively and saw …

AirSculpt Technologies shares plunge 13% after revenue miss and weaker EBITDA outlook

AirSculpt Technologies (NASDAQ:AIRS) shares dropped 13% in pre-market trading after the company reported lower-than-expected second-quarter fiscal 2026 revenue and revised down its full-year adjusted EBITDA forecast. Despite stable same-center case volumes, revenue per case declined, and increased marketing investments further impacted profitability, leading to …

Scully Royalty adopts new policy for transparent shareholder director nominations.

Scully Royalty Ltd. has implemented an Advance Notice Policy to create a clear and structured process for shareholder nominations of directors. This policy ensures timely and accurate disclosure of nominee information, helping shareholders assess candidates' qualifications and independence. The policy aligns with the company's …

Earnings call transcript: AirSculpt Q2 2026 revenue miss sparks sharp premarket drop

AirSculpt Technologies (NASDAQ: AIRS) posts Q2 2026 loss but cuts debt load

AirSculpt Technologies (NASDAQ: AIRS) reported a net loss of $1.1 million for Q2 2026 and $3.5 million for the first half of 2026, with revenue slightly down compared to the previous year. Despite the losses and increased customer acquisition costs, the company improved its …

Airsculpt Technologies, Inc. 2Q 2026: Revenue $42.9M, EPS ($0.02) — 10-Q Summary

Airsculpt Technologies, Inc. (AIRS) reported second-quarter 2026 results with revenue of $42.9 million and a diluted loss per share of ($0.02), indicating a wider net loss compared to the previous year. Revenue declined about 3% year-over-year due to modest average selling price declines, while …

Dekon Food and Agriculture Group Posts Higher Hog Prices, Softer Poultry Margins in July

Airsculpt Technologies, Barrick Mining And Other Big Stocks Moving Lower In Monday’s Pre-Market Session

Several prominent stocks, including AirSculpt Technologies and Barrick Mining, saw declines in pre-market trading on Monday. AirSculpt Technologies dipped after missing sales expectations and narrowing its FY2026 sales guidance, while Barrick Mining also fell following its second-quarter results. Other companies like Jinxin Technology Holding …

Oculis Holding (OCS) inks $3.8M cash-plus-shares deal for Privosegtor rights

Oculis Holding AG has agreed to acquire full development and commercial rights to Privosegtor (ACT-01) and preclinical candidate ACT-02 from Accure Therapeutics for an upfront cash payment of $3.8 million and up to 2,050,000 Oculis ordinary shares. This deal terminates a prior licensing agreement, …

AirSculpt Technologies (NASDAQ:AIRS) Posts Earnings Results

AirSculpt Technologies (NASDAQ:AIRS) recently reported its quarterly earnings, missing analyst estimates with an EPS of $0.01 against a $0.02 consensus and revenue of $42.90 million, below the $44.14 million forecast. The company also posted a negative net margin of 7.39%. Despite one upgrade to …

LeMaitre Vascular (LMAT) Has A Fresh Update, So Why Is It Drawing Attention?

LeMaitre Vascular (LMAT) recently released strong second-quarter 2026 results with increased sales and net income, alongside updated guidance and a reaffirmed cash dividend. Despite positive long-term shareholder returns, recent share price performance has been weak. The stock is considered undervalued by analysts, trading 31.4% …

Scully Royalty Board Adopts Advance Notice Policy for Director Nominations

Scully Royalty Ltd. (NYSE: SRL) has announced that its Board of Directors adopted an Advance Notice Policy for director nominations, effective immediately. This Policy aims to establish a transparent and orderly process for shareholder nominations, ensuring the Company and its shareholders receive timely and …

AirSculpt Technologies Non-GAAP EPS of $0.01, revenue of $42.9M; reaffirms FY 2026 outlook

* AirSculpt Technologies press release [https://seekingalpha.com/pr/20612512-airsculpt-technologies-reports-second-quarter-fiscal-2026-results] (AIRS [https://seekingalpha.com/symbol/AIRS]): Q2 Non-GAAP EPS of $0.01. * Revenue of $42.9M (-2.5% Y/Y). * Case volume was 3,376 for the second quarter of 2026, representing a (0.5)% decrease from the fiscal year 2025 second quarter case volume of …

AirSculpt Technologies Reports Second Quarter 2026 Results, Reaffirms Full-Year Revenue Outlook and Lowers Adjusted EBITDA Guidance

AirSculpt Technologies announced its Q2 2026 results, showing a slight revenue decline to $42.9 million and a net loss of $1.1 million, but also positive momentum in same-center case volume and stable sales. The company reaffirmed its full-year revenue guidance at the lower end …

IMDX Stock Price and Chart — NASDAQ:IMDX

This article provides an overview of Insight Molecular Diagnostics Inc. (IMDX) stock, including its current price, market capitalization, key financial stats, and performance over various periods. It also highlights analyst opinions, future earnings expectations, and company details, noting the FDA review for GraftAssureDx and …

Scully Royalty Ltd. (NYSE: SRL) sets new advance notice rules for board nominees

Scully Royalty Ltd. (NYSE: SRL) has adopted a supplemental Advance Notice Policy, effective immediately, to govern shareholder nominations for its Board of Directors. This policy, which supplements the company’s existing Articles of Association, sets detailed requirements for nomination notices, including extensive disclosures from nominating …

AirSculpt Technologies (AIRS) cuts 2026 EBITDA outlook as Q2 revenue slips

Hercules Capital (HTGC) Is Up 5.1% After Strong Q2 Earnings And Supplemental Dividend Announcement

Hercules Capital (HTGC) saw a 5.1% increase in stock price following strong Q2 2026 earnings, reporting increased revenue and net income. The company also announced a regular quarterly dividend of US$0.47 per share and a supplemental distribution of US$0.07, reinforcing its commitment to shareholder …

Quantinno Capital Management LP Buys 18,204 Shares of LeMaitre Vascular, Inc. $LMAT

Quantinno Capital Management LP significantly increased its stake in LeMaitre Vascular, Inc. by 357.4%, acquiring 18,204 additional shares. This brings their total holding to 23,298 shares, valued at approximately $2.54 million. The news comes as LeMaitre Vascular faces mixed analyst sentiment due to missing …

Scully Royalty Ltd. Board of Directors Adopts Advance Notice Policy for Director Nominations

Scully Royalty Ltd. (NYSE: SRL) has announced that its Board of Directors adopted an Advance Notice Policy for director nominations, effective immediately. This Policy aims to establish a transparent and orderly process for shareholder nominations, ensuring the Company and its shareholders receive timely and …

Oculis to Acquire Full Global Rights to Privosegtor from Accure Therapeutics in Strategic Asset Purchase

Oculis Holding AG announced a strategic asset purchase agreement to acquire the global development and commercial rights to Privosegtor and future candidate ACT-02 from Accure Therapeutics. This deal, valued at $3.8 million upfront cash and up to 2,050,000 Oculis ordinary shares, terminates their previous …

Oculis acquires full rights to Privosegtor, boosting its neuro-ophthalmology drug pipeline and cutting royalties.

Oculis Holding AG has acquired all worldwide rights to Privosegtor from Accure Therapeutics for an upfront cash payment of $3.8 million and up to 2,050,000 Oculis shares, with the deal expected to close by early 2027. This acquisition ends their previous license agreement and …

Oculis undirritar kaupsamning við Accure Therapeutics um leiðandi þróunarlyfið Privosegtor og eflir þannig stöðu Oculis sem leiðandi vaxtarfyrirtækis á sviði taugaaugnlækninga

ZUG, Sviss og BARSELÓNA, Spáni, ágúst 10, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” eða “félagið”), alþjóðlegt líftæknifyrirtæki með áherslu á nýsköpun til að mæta brýnni þörf fyrir meðferðir við augnsjúkdómum og augntaugasjúkdómum, og Accure Therapeutics, S.L. (“Accure”), rannsóknar- og …

Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company

ZUG, Switzerland and BARCELONA, Spain, August 10, 2026 Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, and Accure Therapeutics, S.L. (“Accure”), a …

Insight Molecular Diagnostics earnings beat, revenue fell short of estimates By Investing.com

Insight Molecular Diagnostics (NASDAQ: IMDX) reported second-quarter EPS of $-0.230, exceeding analyst estimates of $-0.240. However, the company's revenue of $240K fell short of the consensus estimate of $470.85K. Despite the revenue miss, the company's stock price has shown significant volatility, being down -25.700% …

Moleculin Biotech Inc (MBRX) Earnings Forecast: Future EPS & Revenue Growth Estimates

AirSculpt Technologies stock tumbles 13% on revenue miss, weak guidance

AirSculpt Technologies (NASDAQ:AIRS) saw its stock tumble 13.17% in pre-market trading after reporting second-quarter fiscal 2026 results that missed revenue expectations and included reduced adjusted EBITDA guidance. While adjusted EPS met analyst estimates at $0.01, revenue of $42.9 million fell short of the $44.2 …

Culp Inc (CULP) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Culp Inc (CULP), focusing on future EPS and revenue growth estimates. It highlights key financial metrics such as market capitalization and current stock price, along with sections for news, analysis, financials, and technical forecasts. The information is …